We are live on ! Find out more
PVCT

PROVECTUS BIOPHARMACEUTICALS, INC. (DE)
PVCT

Delisted

PVCT was delisted on the 13th of October, 2016.

Back to rankings

6 hedge funds and large institutions have $21.2K invested in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in 2024 Q4 according to their latest regulatory filings, with funds opening new positions, increasing their positions, 0 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

5% less capital invested

Capital invested by funds: $22.3K → $21.2K (-$1.09K)

14% less funds holding

Funds holding: 7 → 6 (-1)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
6
Holders Change
-1
Holders Change %
-14.29%
% of All Funds
0.08%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
LDB
Lee, Danner & Bass
Tennessee
-$5K
Name Holding Trade Value Shares
Change 		Change in
Stake
HFBOT
1
Home Federal Bank of Tennessee
Tennessee
$12K – – –
AW
2
Atlas Wealth
Ohio
$3.2K – – –
ACM
3
Academy Capital Management
Texas
$2.4K – – –
LIA
4
LBMC Investment Advisors
Tennessee
$2.4K – – –
FS
5
Financial Symmetry
North Carolina
$1.22K – – –
LDB
6
Lee, Danner & Bass
Tennessee
– -$5K -50,000 Closed

PVCT Hedge Fund Activity: Q4 2024 in Review

6 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) for Q4 2024, worth a combined $21.2K — down 4.9% from $22.3K a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of PVCT and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.

The largest seller was Lee, Danner & Bass, exiting entirely with an estimated $5K sold.

  • 6 institutional investors held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) as of Q4 2024, down from 7 in Q3 2024.
  • Funds reported $21.2K of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) stock for Q4 2024, down 4.9% quarter-over-quarter.
  • 0 funds opened new PROVECTUS BIOPHARMACEUTICALS, INC. (DE) positions in Q4 2024 and 1 closed out, a net change of -1 holder.
  • The largest PROVECTUS BIOPHARMACEUTICALS, INC. (DE) seller in Q4 2024 was Lee, Danner & Bass, an estimated $5K sold.

Based on aggregated 13F filings for Q4 2024.